

Y-MABS THERAPEUTICS AND SWIXX COMPLETE CEE & RUSSIA DEAL ON DANYELZA® AND OMBURTAMAB

SWIXX ANNOUNCEMENT NO. 33

December 18th, 2020

Baar, Switzerland – Swixx BioPharma AG of Baar, Switzerland announced today the signing of a distribution contract with Y-mAbs Therapeutics, Inc. of New York, NY, USA. Under the agreement, Y-mAbs has appointed Swixx as exclusive distributor of both Danyelza®(naxitamab-gqgk) and omburtamab in the EU territories of Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, and Slovenia. In addition, Swixx will file registrations on behalf of Y-mAbs and distribute both Danyelza® and omburtamab in Russia, Bosnia & Herzegovina and Serbia.

Danyelza® was approved by the FDA on November 25th, 2020, and Y-mAbs plans to resubmit its BLA to the FDA for omburtamab in early 2021. Danyelza® is indicated in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. Omburtamab, if approved, would be indicated for the treatment of pediatric patients with CNS / leptomeningeal metastasis from neuroblastoma. Filing of omburtamab to the European Medicines Agency (EMA) is anticipated in the course of 2021.

“It’s a proud moment for our company to announce that Y-mAbs has determined to partner with Swixx across such a broad territory” commented Dr. Laur Saar, Swixx Head of Medical and Regulatory. It will be a pleasure to assist Y-mAbs to bring these new therapies to children in CEE suffering from neuroblastoma, to their families, physicians and nurses. While thankfully a rare condition, paediatric neuroblastoma is an area of great unmet need for patients, and both naxitamab and omburtamab, if approved, will bring new hope.”

“This contract also represents a significant oncology milestone for Swixx,” remarked Dr. Dezso Martha, Swixx’s Chief Operating Officer. “We had not, until now, signed an oncology compound for the entire Eastern half of Europe, including our new subsidiary in Russia. We do appreciate Y-mAbs confidence in Swixx to bring these important, life-saving medicines to children from Vladivostok to Sofia – across some nine time zones! Our Swixx country teams will work hard to swiftly register and make these important therapies available as soon as humanly possible, and we stand ready to expedite treatment wherever necessary, relying on Y-mAbs’ partnership. It’s been a privilege to work with Y-mAbs’ New York and Copenhagen teams over the past months, and we look forward to a long and productive relationship as we tackle the challenge of bringing these promising new medicines to CEE patients.”

About Swixx BioPharma AG

Swixx operates fully owned subsidiaries across Central and Eastern Europe and Russia. With 550 employees and sales exceeding 200M Euros in 2020, Swixx is now the largest and fastest-growing dedicated agent for biopharma and self-medication innovative companies in CEE. The company has gathered outstanding rare disease, oncology-haematology, specialty and self-medication talent under one roof.

For more information about Swixx, please visit: www.swixxbiopharma.com

About Y-mAbs

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA[®] (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3. Researchers at Memorial Sloan Kettering Cancer Center (MSK) developed DANYELZA and omburtamab, which are exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests in the compounds and in Y-mAbs.

“DANYELZA” and “Y-mAbs” are registered trademarks of Y-mAbs Therapeutics, Inc.

For more information about Y-mAbs, please visit: www.ymabs.com

Contact: Maja Boskovic, Public Affairs Officer, Swixx BioPharma A.G.

Maja.Boskovic@swixxbiopharma.com Tel: +381 11 4426 321

Note on Unsubscribing from Swixx Announcement Mailing List: In accordance with the European Union’s GDPR (General Data Protection Regulation) provisos, should you wish to unsubscribe / opt out of our mailing list, please send to Maja.Boskovic@swixxbiopharma.com a one-line message “Please unsubscribe me.”